Do analysts prefer CERS or UTMD?

Cerus currently has a consensus price target of $5.25, indicating a potential upside of 110.84%. Given Cerus' stronger consensus rating and higher possible upside, research analysts clearly believe Cerus is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor CERS or UTMD?

In the previous week, Cerus and Cerus both had 2 articles in the media. Cerus' average media sentiment score of 1.77 equaled Utah Medical Products'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Utah Medical Products 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate UTMD or SMTI?

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.23%. Given Sanara MedTech's higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media prefer UTMD or SMTI?

In the previous week, Utah Medical Products and Utah Medical Products both had 2 articles in the media. Utah Medical Products' average media sentiment score of 1.77 beat Sanara MedTech's score of 0.92 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate UTMD or EMBC?

Embecta has a consensus price target of $11.00, suggesting a potential upside of 122.67%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Does the media prefer UTMD or EMBC?

In the previous week, Embecta had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 5 mentions for Embecta and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.77 beat Embecta's score of 1.28 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Embecta 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer UTMD or RXST?

RxSight has a consensus price target of $8.37, suggesting a potential upside of 38.98%. Given RxSight's higher possible upside, analysts plainly believe RxSight is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 RxSight 3 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.91

Does the media prefer UTMD or RXST?

In the previous week, RxSight had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 5 mentions for RxSight and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.77 beat RxSight's score of 0.66 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RxSight 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ACU or UTMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acme United 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ACU or UTMD?

In the previous week, Acme United and Acme United both had 2 articles in the media. Utah Medical Products' average media sentiment score of 1.77 beat Acme United's score of 0.92 indicating that Utah Medical Products is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acme United 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Utah Medical Products 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Utah Medical Products (UTMD) Competitors

$69.71 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$69.79 +0.08 (+0.11%)

As of 08:42 AM Eastern

Compare

UTMD vs. CERS, SMTI, EMBC, RXST, and ACU

Should you buy Utah Medical Products stock or one of its competitors? Utah Medical Products's main competitors and comparable companies include Cerus (CERS), Sanara MedTech (SMTI), Embecta (EMBC), RxSight (RXST), and Acme United (ACU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Utah Medical Products compare to Cerus?

Cerus (NASDAQ:CERS) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Utah Medical Products has lower revenue, but higher earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.43	-$15.63M	-$0.03	N/A
Utah Medical Products	$38.52M	5.75	$11.29M	$3.28	21.25

In the previous week, Cerus and Cerus both had 2 articles in the media. Cerus' average media sentiment score of 1.77 equaled Utah Medical Products'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Utah Medical Products	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cerus has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Cerus currently has a consensus price target of $5.25, indicating a potential upside of 110.84%. Given Cerus' stronger consensus rating and higher possible upside, research analysts clearly believe Cerus is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.4% of Cerus shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Utah Medical Products has a net margin of 29.04% compared to Cerus' net margin of -3.06%. Utah Medical Products' return on equity of 8.74% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Utah Medical Products	29.04%	8.74%	8.50%

Summary

Utah Medical Products beats Cerus on 8 of the 14 factors compared between the two stocks.

How does Utah Medical Products compare to Sanara MedTech?

Utah Medical Products (NASDAQ:UTMD) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Utah Medical Products has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by company insiders. Comparatively, 42.0% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Utah Medical Products has a net margin of 29.04% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Utah Medical Products' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
Sanara MedTech	-29.15%	29.72%	2.84%

Sanara MedTech has a consensus target price of $35.00, suggesting a potential upside of 0.23%. Given Sanara MedTech's higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Utah Medical Products has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	5.75	$11.29M	$3.28	21.25
Sanara MedTech	$103.12M	3.11	-$37.56M	-$3.59	N/A

In the previous week, Utah Medical Products and Utah Medical Products both had 2 articles in the media. Utah Medical Products' average media sentiment score of 1.77 beat Sanara MedTech's score of 0.92 indicating that Utah Medical Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utah Medical Products	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Utah Medical Products beats Sanara MedTech on 9 of the 14 factors compared between the two stocks.

How does Utah Medical Products compare to Embecta?

Utah Medical Products (NASDAQ:UTMD) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 8.0% of Utah Medical Products shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Utah Medical Products has a net margin of 29.04% compared to Embecta's net margin of 8.59%. Utah Medical Products' return on equity of 8.74% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Embecta had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 5 mentions for Embecta and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.77 beat Embecta's score of 1.28 indicating that Utah Medical Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utah Medical Products	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Embecta	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Embecta has a consensus price target of $11.00, suggesting a potential upside of 122.67%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Utah Medical Products pays an annual dividend of $1.24 per share and has a dividend yield of 1.8%. Embecta pays an annual dividend of $0.04 per share and has a dividend yield of 0.8%. Utah Medical Products pays out 37.8% of its earnings in the form of a dividend. Embecta pays out 2.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Utah Medical Products has raised its dividend for 3 consecutive years. Utah Medical Products is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Embecta has higher revenue and earnings than Utah Medical Products. Embecta is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	5.75	$11.29M	$3.28	21.25
Embecta	$1.08B	0.26	$95.40M	$1.48	3.34

Summary

Utah Medical Products beats Embecta on 10 of the 18 factors compared between the two stocks.

How does Utah Medical Products compare to RxSight?

Utah Medical Products (NASDAQ:UTMD) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

RxSight has a consensus price target of $8.37, suggesting a potential upside of 38.98%. Given RxSight's higher possible upside, analysts plainly believe RxSight is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
RxSight	3 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.91

Utah Medical Products has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, RxSight has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Utah Medical Products has a net margin of 29.04% compared to RxSight's net margin of -36.80%. Utah Medical Products' return on equity of 8.74% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
RxSight	-36.80%	-17.35%	-14.70%

In the previous week, RxSight had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 5 mentions for RxSight and 2 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.77 beat RxSight's score of 0.66 indicating that Utah Medical Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utah Medical Products	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RxSight	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Utah Medical Products has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	5.75	$11.29M	$3.28	21.25
RxSight	$134.48M	1.86	-$38.94M	-$1.13	N/A

69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Utah Medical Products beats RxSight on 9 of the 16 factors compared between the two stocks.

How does Utah Medical Products compare to Acme United?

Acme United (NYSE:ACU) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Utah Medical Products has a net margin of 29.04% compared to Acme United's net margin of 10.25%. Acme United's return on equity of 9.70% beat Utah Medical Products' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acme United	10.25%	9.70%	6.10%
Utah Medical Products	29.04%	8.74%	8.50%

Acme United pays an annual dividend of $0.64 per share and has a dividend yield of 1.1%. Utah Medical Products pays an annual dividend of $1.24 per share and has a dividend yield of 1.8%. Acme United pays out 26.9% of its earnings in the form of a dividend. Utah Medical Products pays out 37.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Acme United has raised its dividend for 20 consecutive years and Utah Medical Products has raised its dividend for 3 consecutive years.

In the previous week, Acme United and Acme United both had 2 articles in the media. Utah Medical Products' average media sentiment score of 1.77 beat Acme United's score of 0.92 indicating that Utah Medical Products is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acme United	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Utah Medical Products	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Acme United has higher revenue and earnings than Utah Medical Products. Utah Medical Products is trading at a lower price-to-earnings ratio than Acme United, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acme United	$211.60M	1.09	$17.79M	$2.38	25.51
Utah Medical Products	$38.52M	5.75	$11.29M	$3.28	21.25

Acme United has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

62.1% of Acme United shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 29.5% of Acme United shares are held by insiders. Comparatively, 8.0% of Utah Medical Products shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acme United	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Acme United beats Utah Medical Products on 9 of the 17 factors compared between the two stocks.

Get Utah Medical Products News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTMD vs. The Competition

Export

Metric	Utah Medical Products	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$221.68M	$5.40B	$7.15B	$12.84B
Dividend Yield	1.78%	1.80%	2.57%	11.71%
P/E Ratio	21.25	25.09	275.28	25.35
Price / Sales	5.75	71.63	646.14	90.72
Price / Cash	15.62	33.03	28.42	34.96
Price / Book	1.87	5.97	10.37	6.21
Net Income	$11.29M	$150.75M	$3.50B	$358.54M
7 Day Performance	-1.95%	-2.75%	-3.30%	-2.39%
1 Month Performance	-1.82%	-3.35%	-0.86%	-3.39%
1 Year Performance	11.88%	9.46%	23.53%	8.81%

Utah Medical Products Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTMD Utah Medical Products	1.4043 of 5 stars	$69.71 flat	N/A	+11.9%	$221.68M	$38.52M	21.25	180	Positive News
CERS Cerus	1.9755 of 5 stars	$2.54 -1.9%	$5.25 +106.7%	+102.4%	$521.95M	$221.55M	N/A	290
SMTI Sanara MedTech	0.6504 of 5 stars	$35.05 +0.9%	$35.00 -0.1%	+2.8%	$319.10M	$103.12M	N/A	60
EMBC Embecta	3.6574 of 5 stars	$5.55 -4.3%	$11.00 +98.2%	-67.1%	$314.46M	$1.02B	3.75	1,850	Positive News
RXST RxSight	3.1998 of 5 stars	$6.45 +1.1%	$8.37 +29.7%	-35.3%	$265.16M	$127.58M	N/A	220	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTMD) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Utah Medical Products (UTMD) Competitors

UTMD vs. CERS, SMTI, EMBC, RXST, and ACU

How does Utah Medical Products compare to Cerus?

Summary

How does Utah Medical Products compare to Sanara MedTech?

Summary

How does Utah Medical Products compare to Embecta?

Summary

How does Utah Medical Products compare to RxSight?

Summary

How does Utah Medical Products compare to Acme United?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTMD vs. The Competition

Utah Medical Products Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Utah Medical Products (UTMD) Competitors

UTMD vs. CERS, SMTI, EMBC, RXST, and ACU

How does Utah Medical Products compare to Cerus?

Which has better earnings & valuation, CERS or UTMD?

Does the media favor CERS or UTMD?

Which has more volatility and risk, CERS or UTMD?

Do analysts prefer CERS or UTMD?

Do institutionals & insiders believe in CERS or UTMD?

Is CERS or UTMD more profitable?

Summary

How does Utah Medical Products compare to Sanara MedTech?

Which has more risk & volatility, UTMD or SMTI?

Do institutionals and insiders believe in UTMD or SMTI?

Is UTMD or SMTI more profitable?

Do analysts rate UTMD or SMTI?

Which has stronger valuation & earnings, UTMD or SMTI?

Does the media prefer UTMD or SMTI?

Summary

How does Utah Medical Products compare to Embecta?

Do insiders & institutionals have more ownership in UTMD or EMBC?

Which has more volatility & risk, UTMD or EMBC?

Is UTMD or EMBC more profitable?

Does the media prefer UTMD or EMBC?

Do analysts rate UTMD or EMBC?

Is UTMD or EMBC a better dividend stock?

Which has preferable valuation and earnings, UTMD or EMBC?

Summary

How does Utah Medical Products compare to RxSight?

Do analysts prefer UTMD or RXST?

Which has more volatility and risk, UTMD or RXST?

Is UTMD or RXST more profitable?

Does the media prefer UTMD or RXST?

Which has preferable earnings and valuation, UTMD or RXST?

Do insiders and institutionals hold more shares of UTMD or RXST?

Summary

How does Utah Medical Products compare to Acme United?

Is ACU or UTMD more profitable?

Is ACU or UTMD a better dividend stock?

Does the media favor ACU or UTMD?

Which has stronger valuation and earnings, ACU or UTMD?

Which has more volatility and risk, ACU or UTMD?

Do institutionals & insiders have more ownership in ACU or UTMD?

Do analysts rate ACU or UTMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTMD vs. The Competition

Utah Medical Products Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools